Reuters logo
3 years ago
BRIEF-Genticel licenses Vaxiclase platform to Serum Institute of India
February 2, 2015 / 5:47 PM / 3 years ago

BRIEF-Genticel licenses Vaxiclase platform to Serum Institute of India

Feb 2 (Reuters) - Genticel SA :

* Signs licensing agreement with Serum Institute of India for use of its Vaxiclase platform

* License agreement allows Genticel to receive up to $57 million upfront and milestone payments, as well as single-digit royalties on net sales

* Agreement is in context of vaccine development against whooping cough

Source text: bit.ly/1DxrvTJ Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below